Target intelligence / Profile preview

Formin-like protein 2 (FMNL2)

Target
FMNL2
Molecular classification
Cytoskeletal protein, Actin-binding protein, Formin family
01

Overview

Formin-like protein 2 (FMNL2) is an evolutionarily conserved actin-binding protein from the formin family, primarily involved in modulating cytoskeletal organization. It participates in the formation of actin filaments, cell migration, invasion, polarity, and adhesion. FMNL2 is activated downstream of Rho GTPases like Cdc42 and Rac1. Functionally, FMNL2 regulates filopodia and lamellipodia assembly through its formin homology domains, mediating cell protrusions crucial for migration and extracellular navigation[2][3][6][7]. FMNL2 has clinical relevance in cancer (regulating cell invasion, particularly in breast and colorectal cancer), neurodegenerative (Alzheimer’s disease), cardiovascular, and some ocular diseases (glaucoma)[1][3][4][5][7]. Formin proteins, including FMNL2, are not common direct drug targets, but represent critical nodes in pathways relevant to disease progression and cellular physiology. FMNL2’s potential as a biomarker exists in oncology and neurovascular disease contexts.

Other names
FMNL2FHOD2Formin-like protein 2Formin homology 2 domain-containing protein 2KIAA1902FRL3
02

Mechanism of action

For FMNL2-targeting strategies (investigational/restorative): Modulation of actin polymerization; Inhibition or enhancement of cellular migration/invasion via Rho GTPase effector pathways[1][2][7].

03

Biological functions

Actin polymerization and cytoskeletal organizationCell migration and invasionCell adhesion and junction integrityCell morphology, motility, and shape regulationMorphogenesis and polarityFilopodia and lamellipodia formationCytokinesis
04

Disease associations

Cancer (migration, invasion, metastasis, e.g., breast and colorectal cancer)Neurodegenerative disease (Alzheimer’s disease, regulation of gliovascular interactions)Glaucoma (cytoskeletal roles in trabecular meshwork)Cardiovascular disease (association with vascular risk factors)Inflammatory Bowel Disease and Crohn’s Disease
05

Safety considerations

Therapeutic targeting of actin polymerization and cytoskeletal dynamics could produce broad off-target effects leading to cytotoxicity, defective cell adhesion, impaired wound healing, or immune cell dysregulationClinical safety profiles are unclear due to lack of FMNL2-specific drugs
06

Biomarkers

FMNL2 expression/protein levels for prognosis and disease monitoring in breast cancer, colorectal cancer, and possibly Alzheimer’s diseaseFMNL2 polymorphisms/SNPs in certain genetic risk studies for Alzheimer’s and cardiovascular disease

Beyond the preview

Go deeper on Formin-like protein 2 (FMNL2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Formin-like protein 2 (FMNL2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call